Gastric Cancer Treatment Market, By Treatment (Surgery, Chemo Therapy, Adjuvant Chemotherapy, Targeted Drugs Therapy (Sunitinib (Sutent), Trastuzumab (Herceptin), and Imatinib (Gleevec)), and Radiation Therapy), By End-User (Hospitals, Clinics, Specialized Cancer Treatment Centers, and Ambulatory Surgical Centers), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa - Trends, Analysis and Forecast till 2034

Report Code: PMI265419 | Publish Date: March 2024 | No. of Pages: 178

Global Gastric Cancer Treatment Market Companies

  • Eli Lilly and Company
  • F.Hoffman-La Roche Ltd
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Novartis International AG
  • Otsuka Holdings Co. Ltd
  • Bristol-Myers Squibb Company
  • Pfizer, Inc
  • Celltrion, Inc

Recent News:

  • In March 2023, Akeso, Inc. completes patient recruitment for a pivotal Phase III clinical trial involving cadonilimab (PD-1/CTLA-4 bispecific antibody, AK104), considered a pioneering dual-site immunoassay in the world. Specific antibody-based drugs must be approved and marketed. This marks another step toward the launch of cadonilimab for a primary indication following its approval for the treatment of cervical cancer.
  • In January 2023, Eisai Co., Ltd. publishes a research presentation on different types of gastrointestinal cancers at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium this year 2023 (#GI23), taking place live in San Francisco, California.